9IN - HDAC inhibitors and check point inhibitors

Date 05 March 2018
Event TAT 2018 - Targeted Anticancer Therapies
Session Novel epigenetic targets
Topics Anticancer Agents
Presenter René Bartz
Citation Annals of Oncology (2018) 29 (suppl_3): iii1-iii6. 10.1093/annonc/mdy046
Authors R. Bartz
  • -, 4SC AG, 82152 - Planegg/DE


Despite successes in the treatment of melanoma patients with checkpoint inhibitors (CI), most patients do not respond to CI alone and a high unmet medical need remains for these patients. One promising approach is to enhance the immunogenicity and alter the tumor microenvironment from a more immune-deserted to an immune-inflamed phenotype by means of combination therapy. Epigenetic modulation has been reported as one key determining factor in shaping the immune microenvironment and compounds altering these processes (e.g. histone deacetylases (HDAC) inhibitors) are particularly promising.